What is the relationship between cannabis hyperemesis syndrome and thiamine deficiency?

Relationship Between Cannabis Hyperemesis Syndrome and Thiamine Deficiency

There is no established direct pathophysiologic relationship between cannabis hyperemesis syndrome (CHS) and thiamine deficiency, but patients with CHS are at significant risk for developing thiamine deficiency due to prolonged vomiting and malnutrition, which can lead to life-threatening complications including Wernicke encephalopathy.

Understanding the Clinical Connection

The 2024 AGA guidelines on CHS 111111111 comprehensively describe the pathophysiology, diagnosis, and management of CHS but make no mention of thiamine deficiency as part of the syndrome itself. CHS is fundamentally a disorder of gut-brain interaction mediated by cannabinoid receptor dysregulation, particularly CB1 receptors in the dorsal vagal complex, leading to cyclic vomiting episodes.

However, the clinical consequence of CHS—severe, recurrent vomiting—creates a high-risk scenario for thiamine depletion. Case reports demonstrate this dangerous intersection: a 16-year-old with CHS developed Wernicke encephalopathy despite no alcohol use history 2, and a 41-year-old heavy cannabis user with CHS-induced vomiting developed Wernicke encephalopathy with seizures and memory deficits 3.

Why CHS Patients Are at Risk for Thiamine Deficiency

Thiamine reserves deplete rapidly—within 20 days of inadequate oral intake 4. CHS patients face multiple risk factors:

• Prolonged vomiting episodes lasting days to weeks, preventing adequate oral intake
• Malabsorption from chronic cannabis use affecting gastrointestinal function
• Poor nutritional quality of foods consumed during cannabis use, despite the common misconception that cannabis induces hyperphagia 3
• Increased metabolic demands during acute illness phases

The ESPEN micronutrient guidelines 4 identify patients with poor oral intake, malnutrition, increased gastrointestinal losses, and critical illness as high-risk groups—all applicable to CHS patients during acute episodes.

Critical Clinical Implications

Any patient presenting with CHS and neurologic symptoms (confusion, ataxia, ophthalmoplegia, memory deficits) should be presumed to have Wernicke encephalopathy until proven otherwise 23. This is a medical emergency requiring immediate thiamine administration.

Recommended Thiamine Dosing for CHS Patients:

For suspected or proven Wernicke encephalopathy:

• 500 mg IV three times daily until symptoms resolve 4
• Administer before any glucose-containing fluids to prevent precipitating acute Wernicke encephalopathy

For CHS patients with prolonged vomiting (>3-5 days) without encephalopathy:

• 200-300 mg IV daily for at least 3 days 4
• This mirrors refeeding syndrome prophylaxis, which is appropriate given similar risk profiles

For maintenance after acute treatment:

• 50-100 mg daily orally 4

Common Pitfalls to Avoid

1. Assuming cannabis users are well-nourished: Unlike alcohol users who are routinely given thiamine, cannabis users are often presumed to have adequate nutrition due to the "munchies" phenomenon. This is a dangerous misconception 3.

2. Waiting for laboratory confirmation: Thiamine levels take time to result. Clinical suspicion alone warrants immediate IV thiamine administration—there is no toxicity risk and no upper limit 4.

3. Using inadequate doses: The oral route and low doses (10-50 mg) are insufficient during acute illness. IV administration with doses of 200-500 mg is required for patients with significant vomiting 4.

4. Missing the diagnosis of Wernicke encephalopathy: The classic triad (confusion, ataxia, ophthalmoplegia) is present in only 10-16% of cases. Any altered mental status in a vomiting CHS patient should trigger empiric high-dose IV thiamine 2.

Practical Clinical Algorithm

For any CHS patient presenting to the ED:

1. Assess duration and severity of vomiting

   • <3 days with good oral intake: Consider oral thiamine 50-100 mg daily
   • ≥3 days or unable to tolerate oral intake: Give 200-300 mg IV thiamine immediately

2. Screen for neurologic symptoms

   • Any confusion, memory problems, gait instability, or eye movement abnormalities: Give 500 mg IV thiamine three times daily immediately 4
   • Obtain brain MRI looking for bilateral thalamic hyperintensities on T2 FLAIR 23

3. Continue prophylaxis during hospitalization

   • 100-300 mg IV daily for all hospitalized CHS patients 4
   • Transition to oral 50-100 mg daily upon discharge with reliable oral intake

4. Long-term management

   • Counsel on cannabis cessation (definitive treatment for CHS) 11
   • Prescribe oral thiamine 50-100 mg daily for at least 6 weeks after resolution of acute episode 4

The evidence strongly supports a low threshold for empiric thiamine supplementation in CHS patients, given the catastrophic consequences of untreated Wernicke encephalopathy and the complete safety profile of thiamine administration 423.